A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Phase I Study ◽

Advanced Solid Tumors ◽

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-1847-5 ◽

2012 ◽

Vol 69 (6) ◽

pp. 1413-1422 ◽

Cited By ~ 51

Author(s):

Mei Dong ◽

Zhi-Qiang Ning ◽

Pu-Yuan Xing ◽

Jia-Lian Xu ◽

Hai-Xiang Cao ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Phase I Study ◽

Advanced Solid Tumors ◽

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-13-0735 ◽

2013 ◽

Vol 19 (19) ◽

pp. 5494-5504 ◽

Cited By ~ 34

Author(s):

André T. Brunetto ◽

Joo Ern Ang ◽

Rohit Lal ◽

David Olmos ◽

L. Rhoda Molife ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Deacetylase Inhibitor ◽

Human Pharmacokinetic

586 Phase I study of pan-histone deacetylase inhibitor abexinostat in combination with cisplatin in patients with advanced solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(14)70712-9 ◽

2014 ◽

Vol 50 ◽

pp. 189

Author(s):

M. Campone ◽

N. Isambert ◽

R. Sabatier ◽

H. Castanie ◽

S. Zanetta ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Faculty of 1000 evaluation for A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718050520.793482822 ◽

2013 ◽

Author(s):

Burton Eisenberg

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Phase I Study ◽

Pediatric Patients ◽

Abstract 1172: Phase I study of histone deacetylase inhibitor belinostat in combination with warfarin in patients with solid tumors or hematological malignancies.

10.1158/1538-7445.am2013-1172 ◽

2013 ◽

Cited By ~ 2

Author(s):

Neeraj Agarwal ◽

Mark L. Wade ◽

Julia Batten ◽

Cynthia Davidson ◽

Show-Li Sun ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Phase I Study ◽

Hematological Malignancies ◽

Faculty of 1000 evaluation for A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718050520.793482405 ◽

2013 ◽

Author(s):

Daniel Indelicato

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Phase I Study ◽

Pediatric Patients ◽

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.2552 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2552-2552 ◽

Cited By ~ 3

Author(s):

U. Banerji ◽

L. van Doorn ◽

D. Papadatos-Pastos ◽

P. Debnam ◽

M. Tall ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Advanced Solid Tumors ◽

Deacetylase Inhibitor ◽

Class 1

A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.3024 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3024-3024 ◽

Cited By ~ 1

Author(s):

R. D. Baird ◽

B. Venugopal ◽

R. S. Kristeleit ◽

J. Charlton ◽

M. Blanco-Codesido ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Histone Deacetylase ◽

Advanced Cancer ◽

Phase I Study ◽

Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors

10.1158/1535-7163.targ-09-a185 ◽

2009 ◽

Author(s):

Lillian L. Siu ◽

Sebastien J. Hotte ◽

Eric X. Chen ◽

Hal W. Hirte ◽

Jean Powers ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Clinical Pharmacokinetic ◽

Advanced Solid Tumors ◽

Deacetylase Inhibitor ◽

Pharmacodynamic Study

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

Pediatric Blood & Cancer ◽

10.1002/pbc.24694 ◽

2013 ◽

Vol 60 (11) ◽

pp. 1868-1874 ◽

Cited By ~ 22

Author(s):

Alexandra P. Zorzi ◽

Mark Bernstein ◽

Yvan Samson ◽

Donna A. Wall ◽

Sunil Desai ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Phase I Study ◽

Pediatric Patients ◽